Ann: Appendix 3Y - Change of Director's Inter, page-13

re: Ann: Appendix 3Y - Change of Director'...

mac,

thanks for that. agree that the dilution will be hard to take, but then we all knew it was coming at some stage ... the bergen thing really shafted us, and we have seen that the new management themselves were frustrated with how it all played out ahead of their last placement.

one thing for sure, the amrmadale suite has done few favours over the years for small investors not in the immediate orbit.

I'm hoping for a notes/shares issue that solves their immediate cash problems and gives us the ability to go forward with only 200m shares on issue. cap is low enough that there is still plenty to gain. I am am optimist on the business plan. I truly believe they have a saleable and scalable product suite.

Given potential for tieups and buyups. I see the oppies converson at .14 in two years from now as a complete no brainer ... I would be thinking .25+ is a reasonable shareprice target in that timeframe given it could be in double figures by the end of this year alone.

not saying it will happen, im saying they have the management and the product pipeline to give themselves a shot at making it happen. the fact directors are buying on market speaks volumes to me.